title: Preliminary comparative study on the effect of different chinese drugs for strengthening Pi in antagonizing diet induced obesity.
abstract: OBJECTIVE
  To observe the difference in fatty degree, glucose-lipid disorder and adipose-hormones between diet induced obesity (DIO) rats and diet induced obesity resistance (DIO-R) rats, and to explore the effect and acting mechanism of Chinese drugs for strengthening Pi (CD-SP) and those for both strengthening Pi and dissolving phlegm (CD-SPDP) in inhibiting obesity.
  
  
  METHODS
  Excepting eight rats allocated in the blank control group, the other 54 rats were fed with high-lipid forage for 12 weeks to establish models of obesity. Finally, 30 DIO rats and 8 DIO-R rats (shown by their body weight) were obtained. The DIO rats were divided into three groups, which were given gastric perfusion, respectively, with normal saline (Group A), CD-SP (Group B), and CD-SPDP (Group C). Fourteen weeks later, the animals' body weight (BW), length (BL), blood levels of fasting insulin (FIn), fasting glucose (FBG), triglyceride (TG), cholesterol (TC), leptin (LP), neuropeptide Y (NPY), C-reactive protein (CRP), tumor necrosis factor-alpha(TNF-alpha), adiponectin (AN), and resistin (RS) were measured; insulin resistance index (IRI) was calculated, and the degree of obesity and lipid content in abdominal cavity of rats were estimated. Moreover, the levels of LP, CRP, TNF-alpha, AN and RS in homogenate of rats' adipose tissues (ATH) were determined.
  
  
  RESULTS
  After 12 weeks of high-lipid diet, the BW of DIO rats was higher than that of normal or DIO-R rats. After a 14-week continuous high-lipid diet feeding, in DIO rats, BW, lipid coefficient (LC), and IRI were significantly increased (P<0.01); serum levels of TNF-alpha, LP and AN were lower, NPY was higher, while the ATH levels of LP and AN were lower and TNF-alpha was higher in DIO rats than in DIO-R rats (P<0.05 or P<0.01); blood levels of FBG and lipids in DIO rats showed an increasing trend but was statistically insignificant (P>0.05); no significant difference was found in serum levels of CRP and RS due to the overly high data dispersion. Comparisons of the 3 DIO groups showed that BW, body weight index (BWI), LC and IRI were significantly lowered after treatment (P<0.01) in Group C, while these indexes were not significantly different between Group A and B; the serum levels of TNF-alpha, LP, and AN increased, NPY decreased in Group B and C, ATH levels of LP and AN increased, and TNF-alpha decreased in the two groups; but NPY, LP, and AN in blood and ATH were higher in Group C than those in Group B (P<0.05 or P<0.01).
  
  
  CONCLUSIONS
  CD-SPDP could inhibit DIO and IR, showing that the effect is better than that of CD-SP, and its mechanism is related to promotion of LP and AN secretion and elevation of serum NPY.
authors.affiliation: Internal Medical Department, Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan (250011), China. lixiao617@163.com
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.forename: Ping
authors.initials: P
authors.lastname: Jiang
authors.forename: Chang-geng
authors.initials: CG
authors.lastname: Fu
mesh_terms: D054392:Adipokines / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D004036:Diet, Atherogenic; D004041:Dietary Fats / Q000009:adverse effects; D004353:Drug Evaluation, Preclinical; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use*; D020738:Leptin / Q000097:blood; D008297:Male; D009478:Neuropeptide Y / Q000097:blood; D009765:Obesity / Q000097:blood / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D054392:Adipokines; D001786:Blood Glucose; D004041:Dietary Fats; D004365:Drugs, Chinese Herbal; D020738:Leptin; D009478:Neuropeptide Y; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein
references.citation: Metabolism. 2005 Sep;54(9):1142-6
references.pmid: 16125524
references.citation: Biochem Biophys Res Commun. 2001 Jul 13;285(2):561-4
references.pmid: 11444881
references.citation: Am J Physiol. 1987 Mar;252(3 Pt 2):R471-8
references.pmid: 3548441
references.citation: J Biol Chem. 2001 Apr 6;276(14):11252-6
references.pmid: 11278254
references.citation: Diabetes. 1991 Feb;40(2):280-9
references.pmid: 1991575
references.citation: Diabetes. 1991 Nov;40(11):1397-403
references.pmid: 1936601
references.citation: Biochem Soc Trans. 2006 Nov;34(Pt 5):798-801
references.pmid: 17052201
references.citation: Nature. 2001 Jan 18;409(6818):307-12
references.pmid: 11201732
references.citation: Am J Physiol. 1986 Sep;251(3 Pt 2):R433-40
references.pmid: 3529988
references.citation: Int J Obes Relat Metab Disord. 2000 Nov;24 Suppl 4:S23-7
references.pmid: 11126235